AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan's latest research. With concerns over US drug pricing policies easing and significant patent expirations on the horizon, the focus shifts to pipeline progress to drive growth, the American investment bank reckons, And it says Novo Nordisk (NYSE:NVO) and AstraZeneca PLC (LSE:AZN) are set to lead the way, bolstered by strong mid-term growth and promising news flow.

Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC

Eli Lilly

Pfizer

Leading vaccine makers like Eli Lilly and Co. NYSE: LLY, Pfizer Inc. NYSE: PFE, and AstraZeneca plc NASDAQ: AZN may have faded from the spotlight since the peak of the COVID-19 pandemic, but now there is reason to expect renewed interest. As investors look ahead to the second Trump administration, the incoming president's nomination of outspoken vaccine critic Robert F.

Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.

AstraZeneca's Enhertu included in China's state insurance reimbursement

AstraZeneca's Fasenra, an injectable treatment for severe asthma, is more effective during attacks than the oral steroid that has been the standard of care for 50 years, cutting the need for further treatment by 30%, according to a study published on Wednesday.

AstraZeneca asthma drug more effective during attack than steroids, study finds

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AZN ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your AstraZeneca PLC investment

NEW YORK CITY, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations

Data from a late-stage study shows that treatment with a three-drug combo involving AZN's Truqap benefits patients with an aggressive form of prostate cancer.

AstraZeneca's Combination Therapy Meets Goal in Prostate Cancer Study

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors Contact Levi & Korsinsky For Details

AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

AstraZeneca PLC's (LSE:AZN) Truqap (capivasertib) has shown promising results in a trial for aggressive prostate cancer, improving progression-free survival when combined with standard therapies. The phase III CAPItello-281 trial tested Truqap with abiraterone and androgen deprivation therapy (ADT) against a placebo combination in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, a form of the disease associated with poor outcomes.

AstraZeneca prostate cancer drug shows promising phase III results

NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

Lost Money on AstraZeneca PLC (AZN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

An Investigation Has Commenced on Behalf of AstraZeneca PLC Shareholders. Contact Levi & Korsinsky to Discuss Your AZN Losses

Dollar Tree

3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

AstraZeneca PLC Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - AZN

Levi & Korsinsky Reminds Shareholders of an Investigation into AstraZeneca PLC (AZN) Regarding Potential Securities Fraud Allegations

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today pledged $3.5 million to nonprofit organizations across the US as part of Accelerate Change Together (ACT) on Health Equity, an initiative to improve access, affordability and outcomes for patients in urban, suburban and rural communities. This brings the total contributions from the program to more than $15 million to date. Now in its fourth year, ACT on Health Equity will fund 53 nonprofit programs which aim to improve access to healthcare,.

AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US

UBS has upgraded AstraZeneca PLC (LSE:AZN) to a 'neutral' rating from 'sell' while maintaining its 12-month price target of 11,300 pence. The change follows a 24% drop in AZ's share price over three months, triggered by ongoing investigations in China and disappointing trial data for its cancer drug Dato-DXd.

AstraZeneca upgraded by leading investment bank, but challenges remain - here's why

AstraZeneca PLC (LSE:AZN) and Daiichi Sankyo said they are 'disappointed and disagree' with a decision by the UK medicines regulator not to give the green light to a breast cancer drug they jointly developed. Talks to approve Enhertu for NHS used collapsed over pricing and despite the intervention of Wes Streeting, the health secretary.

AstraZeneca hits out at NICE block to breast cancer drug

The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.

CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC

In its latest outlook for 2025, Goldman Sachs is urging investors to “buy British” as undervalued UK stocks offer an attractive opportunity in Europe's otherwise tepid equity market. The bank highlights that UK shares, particularly those with a domestic focus, are trading at a discount compared to other European and US markets.

Goldman: Buy British for better returns in 2025

NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.

AstraZeneca PLC Being Investigated on Behalf of AstraZeneca PLC Investors, Contact Levi & Korsinsky For Details

GRAIL Inc

MENLO PARK, Calif. , Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC.

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

News for AstraZeneca Stock (AZN)